Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A

Arch Phys Med Rehabil. 2005 Mar;86(3):431-5. doi: 10.1016/j.apmr.2004.03.034.

Abstract

Objective: To determine hip radiographic findings in children with cerebral palsy (CP) treated with botulinum toxin type A (BTX-A).

Design: Retrospective chart review with correlation to radiographic findings.

Setting: Academic center.

Participants: Sixteen subjects with CP.

Intervention: BTX-A treatment to adductor muscles.

Main outcome measure: The Reimers hip migration percentage before and after BTX-A.

Results: Thirty-two hips in 16 children with CP were treated. We examined the effect of initial migration percentage and initial migration percentage age on the change in migration percentage after BTX-A injection. A significant effect for initial migration percentage (<30% or >/=30%; F=19.05, P <.001) and a significant interaction between initial migration percentage and initial migration percentage age (F=7.5, P <.01) was noted. Initial migration percentage age (</=24 mo or >24 mo) was not significant (F=.95, P =.34). Patients who had an initial migration percentage of 30% or more and were less than 24 months old were more likely to have a decrease in migration percentage after BTX-A injection compared with patients who were older than 24 months and who had an initial migration percentage of 30% or more.

Conclusions: Improvement in hip migration percentage after BTX-A injection is a function of age and the initial migration percentage. BTX-A injections to adductor muscles may be beneficial for some children with CP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / drug therapy*
  • Cerebral Palsy / rehabilitation
  • Child, Preschool
  • Female
  • Hip / diagnostic imaging*
  • Humans
  • Infant
  • Male
  • Neuromuscular Agents / therapeutic use*
  • Radiography
  • Retrospective Studies

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A